Fortress Biotech, Inc. engages in the manufacture and commercialization of novel pharmaceutical products and product candidates. The company is headquartered in Bay Harbor Islands, Florida and currently employs 101 full-time employees. The company went IPO on 2011-11-17. The firm has eight marketed prescription pharmaceutical products and over 20 programs in development, with its majority-owned and majority-controlled partners and subsidiaries and partners and subsidiaries it founded and in which it holds significant minority ownership positions. Its portfolio is being commercialized and developed for various therapeutic areas, including oncology, dermatology, and rare diseases. Its dermatology products include Emrosi, Qbrexza, Amzeeq, Zilxi, Exelderm, Targadox, and Luxamend. Its late-stage product candidates include CUTX-101 (copper histidinate injection for Menkes disease), Triplex (cytomegalovirus (CMV) vaccine), and CAEL-101 (monoclonal antibody for AL amyloidosis). Its early and mid-stage product candidates include Dotinurad (urate transporter (URAT1) inhibitor for gout), MB-101 (IL13Rα2 CAR T Cell Program for Glioblastoma), and others.
Follow-Up Questions
Fortress Biotech Inc의 CEO는 누구입니까?
Dr. Adm. Lindsay Rosenwald은 2009부터 회사에 합류한 Fortress Biotech Inc의 Executive Chairman of the Board입니다.
FBIOP 주식의 가격 성능은 어떻습니까?
FBIOP의 현재 가격은 $9.01이며, 전 거래일에 increased 0.08% 하였습니다.
Fortress Biotech Inc의 주요 사업 주제나 업종은 무엇입니까?
Fortress Biotech Inc은 Biotechnology 업종에 속하며, 해당 부문은 Health Care입니다
Fortress Biotech Inc의 시가총액은 얼마입니까?
Fortress Biotech Inc의 현재 시가총액은 $268.2M입니다
Fortress Biotech Inc는 매수, 매도, 아니면 보유해야 하나요?
월스트리트 분석가들에 따르면, 6명의 분석가가 Fortress Biotech Inc에 대한 분석 평가를 실시했으며, 이는 2명의 강력한 매수, 6명의 매수, 1명의 보유, 0명의 매도, 그리고 2명의 강력한 매도를 포함합니다
